1. SuchyFJ, SokolRJ, BalistreriWF. Liver Disease in Children. 4th ed. Cambridge: Cambridge University Press; 2014. CrossRef

2. ScheinbergIH, SternliebI. Wilson's Disease. Major Problems in Internal Medicine, Vol 23. Philadelphia: Saunders; 1984. xii, 171.

3. SaitoT. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr1987;146:261. CrossRef

4. TalyAB, Meenakshi‐SundaramS, SinhaS, et al.Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore)2007;86:112. CrossRef

5. HarryJ. Kayser‐Fleischer ring. A pathological study. Br J Ophthalmol1970;54:794. CrossRef

6. WiebersDO. Renal stones in Wilson's disease. Am J Med1979;67:249. CrossRef

7. FactorSM. The cardiomyopathy of Wilson's disease. Myocardial alterations in nine cases. Virchows Arch A Pathol Anat Histol1982;397:301. CrossRef

8. MindelzunR. Skeletal changes in Wilson's disease. A radiological study. Radiology1970;94:127. CrossRef

9. LeuML. Skin pigmentation in Wilson's disease. JAMA1970;211:1542. CrossRef

10. CarpenterTO. Hypoparathyroidism in Wilson's disease. N Engl J Med1983;309:873. CrossRef

11. JohansenK. Glucose intolerance in Wilson's disease. Normalization after treatment with penicillamine. Arch Intern Med1972;129:587. CrossRef

12. KormanJD, VolenbergI, BalkoJ, et al.Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology2008;48:1168. CrossRef

13. RossME. Late‐onset Wilson's disease with neurological involvement in the absence of Kayser‐Fleischer rings. Ann Neurol1985;17:411. CrossRef

14. StricklandGT. Wilson's disease in the United Kingdom and Taiwan. I. General characteristics of 142 cases and prognosis. II. A genetic analysis of 88 cases. Q J Med1973;42:619.

15. LauJY. Wilson's disease: 35 years' experience. Q J Med1990;75:597.

16. OderW. Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology1993;43:120. CrossRef

17. AndersonP, PopperH. Changes in hepatic structure in Wilson's disease. Am J Pathol1960;36:483.

18. SternliebI. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. Gastroenterology1968;55:483.

19. BullPC. The Wilson disease gene is a putative copper transporting P‐type ATPase similar to the Menkes gene [erratum appears in Nat Genet 1994 Feb;6:214.]. Nat Genet1993;5:327. CrossRef

20. PetrukhinK. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet1993;5:338. CrossRef

21. TanziRE. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet1993;5:344. CrossRef

22. YamaguchiY. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun1993;197:271. CrossRef

23. ShahAB. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype‐phenotype correlation, and functional analyses. Am J Hum Genet1997;61:317. CrossRef

24. Maier‐DobersbergerT. Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction [see comments]. Ann Intern Med1997;127:21. CrossRef

25. Maier‐DobersbergerT. Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis. Gastroenterology1995;109:2015. CrossRef

26. SokolRJ. Abnormal hepatic mitochondrial respiration and cytochrome C oxidase activity in rats with long‐term copper overload. Gastroenterology1993;105:178.

27. SokolRJ. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. Gastroenterology1994;107:1788.

28. MansouriA. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Gastroenterology1997;113:599. CrossRef

29. YamateJ. Macrophage populations and apoptotic cells in the liver before spontaneous hepatitis in Long‐Evans Cinnamon (LEC) rats. J Comp Pathol1999;120:333. CrossRef

30. StrandS. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO‐1/Fas) mediated apoptosis. Nat Med1998;4:588. CrossRef

31. RobertsEA, SchilskyML. Diagnosis and treatment of Wilson disease: an update. Hepatology2008;47:2089. CrossRef

32. SteindlP. Wilson's disease in patients presenting with liver disease: a diagnostic challenge [see comments]. Gastroenterology1997;113:212. CrossRef

33. FrommerDJ. Urinary copper excretion and hepatic copper concentrations in liver disease. Digestion1981;21:169. CrossRef

34. Martins da CostaC, BaldwinD, PortmannB, et al.Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology1992;15:609. CrossRef

35. SmallwoodRA, WilliamsHA, RosenoerVM, et al.Liver‐copper levels in liver disease: studies using neutron activation analysis. Lancet1968;2:1310. CrossRef

36. O'ConnorJA, SokolRJ. Copper metabolism and copper storage disorders. In: SuchyFJ, SokolRJ, BalistreriWF(eds). Liver Disease in Children. New York City: Cambridge University Press; 2007: 626.

37. ArnonR, CalderonJF, SchilskyM, et al.Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. J Pediatr Gastroenterol Nutr2007;44:596. CrossRef

38. ScheinbergIH, JaffeME, SternliebI. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med1987;317:209. CrossRef

39. AskariFK, Di CiommoV, CalleaF, et al.Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med2003;142:385. CrossRef

40. Starosta‐RubinsteinS, YoungAB, KluinK, et al.Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol1987;44:365. CrossRef

41. BrewerGJ, TerryCA, AisenAM, et al.Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol1987;44:490. CrossRef

42. PallHS, WilliamsAC, BlakeDR. Deterioration of Wilson's disease following the start of penicillamine therapy. Arch Neurol1989;46:359. CrossRef

43. SaitoH, WatanabeK, SaharaM, et al.Triethylene‐tetramine (trien) therapy for Wilson's disease. Tohoku J Exp Med1991;164:29. CrossRef

44. WalsheJM. Thiomolybdates in the treatment of Wilson's disease. Arch Neurol1992;49:132. CrossRef

45. LangCJ, Rabas‐KolominskyP, EngelhardtA, et al.Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol1993;50:1007. CrossRef

46. BrewerGJ, JohnsonV, DickRD, et al.Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow‐up with zinc therapy. Arch Neurol1996;53:1017. CrossRef

47. BrewerGJ, AskariF, LorinczMT, et al.Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double‐blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol2006;63:521. CrossRef

48. PassF, GoldfischerS, SternliebI, et al.Elastosis perforans serpiginosa during penicillamine therapy for Wilson disease. Arch Dermatol1973;108:713. CrossRef

49. SternliebI, FisherM, ScheinbergIH. Penicillamine‐induced skin lesions. J Rheumatol Suppl1981;7:149.

50. RosencrantzR, SchilskyM. Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis2011;31:245. CrossRef

51. WeissKH, GotthardtDN, KlemmD, et al.Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology2011;140:1189. CrossRef

52. SokolRJ, DevereauxM, MierauGW, et al.Oxidant injury to hepatic mitochondrial lipids in rats with dietary copper overload. Modification by vitamin E deficiency. Gastroenterology1990;99:1061.

53. HardieRM, NewtonLH, BruceJC, et al.The changing clinical pattern of Reye's syndrome 1982–1990. Arch Dis Child1996;74:400. CrossRef

54. GlasgowJF, MiddletonB. Reye syndrome – insights on causation and prognosis. Arch Dis Child2001;85:351. CrossRef

55. HallSM. Reye's syndrome and aspirin: a review. Br J Clin Pract Suppl1990;70:4.

56. ForsythBW, HorwitzRI, AcamporaD, et al.New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. JAMA1989;261:2517. CrossRef

57. OrlowskiJP. Whatever happened to Reye's syndrome? Did it ever really exist?Crit Care Med1999;27:1582. CrossRef

58. SchrorK. Aspirin and reye syndrome: a review of the evidence. Paediatr Drugs2007;9:195. CrossRef

59. GlasgowJF. Reye's syndrome: the case for a causal link with aspirin. Drug Saf2006;29:1111. CrossRef

60. BelayED, BreseeJS, HolmanRC, et al.Reye's syndrome in the United States from 1981 through 1997. N Engl J Med1999;340:1377. CrossRef

61. TreemWR. Inborn defects in mitochondrial fatty acid oxidation. In: SuchyFJ, SokolRJ, BalistreriWF(eds). Liver Disease in Children. Philadelphia: Lippincott, Williams & Wilkins; 2001: 735.

62. PartinJC. Reye syndrome. In: SuchyFJ(ed). Liver Disease in Children. St. Louis, MO: CV Mosby; 1994: 653.

63. PerlmutterDH. Alpha‐1‐antitrypsin deficiency. In: SuchyFJ, SokolRJ, BalistreriWF(eds). Liver Disease in Children. New York City: Cambridge University Press; 2007: 523.

64. NelsonDR, TeckmanJ, Di BisceglieAM, et al.Diagnosis and management of patients with α1‐antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol2012;10:575. CrossRef

65. SilvermanEK, SandhausRA. Clinical practice. Alpha1‐antitrypsin deficiency. N Engl J Med2009;360:2749. CrossRef

66. PiitulainenE, CarlsonJ, OhlssonK, et al.Alpha1‐antitrypsin deficiency in 26‐year‐old subjects: lung, liver, and protease/protease inhibitor studies. Chest2005;128:2076. CrossRef

67. ReidCL, WienerGJ, CoxDW, et al.Diffuse hepatocellular dysplasia and carcinoma associated with the Malton variant of alpha 1‐antitrypsin. Gastroenterology1987;93:181.

68. CurielDT, HolmesMD, OkayamaH, et al.Molecular basis of the liver and lung disease associated with the alpha 1‐antitrypsin deficiency allele Mmalton. J Biol Chem1989;264:13938.

69. JanusED, PhillipsNT, CarrellRW. Smoking, lung function, and alpha 1‐antitrypsin deficiency. Lancet1985;1:152. CrossRef

70. GhishanF, GreeneH. Inborn errors of metabolism that lead to permanent liver injury. In: ZakimD, BoyerT(eds). Hepatology: A Textbook of Liver Disease. Philadelphia: W.B. Saunders; 1982: 1351.

71. RabinM, WatsonM, KiddV. Activation of human alpha‐1‐antichymtrypsin and alpha‐1‐antitrypsin genes on human chromosome 14. Somat Cell Mol Genet1986;12:209. CrossRef

72. PierceJA, EradioBG. Improved identification of antitrypsin phenotypes through isoelectric focusing with dithioerythritol. J Lab Clin Med1979;94:826.

73. RegevA, GuaquetaC, MolinaEG, et al.Does the heterozygous state of alpha‐1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case‐control study. J Pediatr Gastroenterol Nutr2006;43:S30. CrossRef

74. DycaicoMJ, GrantG, FeltsK, et al.Neonatal hepatitis induced by alpha 1‐antitrypsin: a transgenic mouse model. Science1988;242:1409. CrossRef

75. CarlsonJA, RogersBB, SifersRN, et al.Accumulation of PiZ alpha 1‐antitrypsin causes liver damage in transgenic mice. J Clin Invest1989;83:1183. CrossRef

76. WuY, WhitmanI, MolmentiE, et al.A lag in intracellular degradation of mutant alpha 1‐antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1‐antitrypsin deficiency. Proc Natl Acad Sci U S A1994;91:9014. CrossRef

77. PerlmutterDH. The role of autophagy in alpha‐1‐antitrypsin deficiency: a specific cellular response in genetic diseases associated with aggregation‐prone proteins. Autophagy2006;2:258. CrossRef

78. PrimhakRA, TannerMS. Alpha‐1 antitrypsin deficiency. Arch Dis Child2001;85:2. CrossRef

79. UdallJNJr, DixonM, NewmanAP, et al.Liver disease in alpha 1‐antitrypsin deficiency. A retrospective analysis of the influence of early breast‐ vs bottle‐feeding. JAMA1985;253:2679. CrossRef

80. SvegerT. The natural history of liver disease in alpha 1‐antitrypsin deficient children. Acta Paediatr Scand1988;77:847. CrossRef

81. CrystalRG. Alpha 1‐antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest1990;85:1343. CrossRef

82. GadekJE, FulmerJD, GelfandJA, et al.Danazol‐induced augmentation of serum alpha 1‐antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest1980;66:82. CrossRef

83. TrulockEP. Lung transplantation for alpha 1‐antitrypsin deficiency emphysema. Chest1996;110:284S. CrossRef

84. TeckmanJH. Lack of effect of oral 4‐phenylbutyrate on serum alpha‐1‐antitrypsin in patients with alpha‐1‐antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr2004;39:34. CrossRef

85. GadekJE, FulmerJD, GelfandJA, et al.Danazol‐induced augmentation of serum alpha 1‐antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest1980;66:82. CrossRef

86. HidvegiT, EwingM, HaleP, et al.An autophagy‐enhancing drug promotes degradation of mutant alpha1‐antitrypsin Z and reduces hepatic fibrosis. Science2010;329:229. CrossRef

87. MarcusNY, PerlmutterDH. Glucosidase and mannosidase inhibitors mediate increased secretion of mutant alpha1 antitrypsin Z. J Biol Chem2000;275:1987. CrossRef

88. DingJ, YannamGR, Roy‐ChowdhuryN, et al.Spontaneous hepatic repopulation in transgenic mice expressing mutant human α1‐antitrypsin by wild‐type donor hepatocytes. J Clin Invest2011;121:1930. CrossRef

89. KappasA, SassaS, GalbraithR. The porphyrias. In: ScriverC, BeaudetA, SlyW(eds). The Metabolic Basis of Inherited Disease. New York: McGraw‐Hill; 1989: 1305.

90. BloomerJ, StrakaJ. Porphyrin metabolism. In: AriasI, JakobyW, PopperH(eds). The Liver, Biology and Pathobiology. New York: Raven; 1988: 451.

91. BloomerJR, BonkovskyHL. The porphyrias. Dis Mon1989;35:1. CrossRef

92. StrakaJG, RankJM, BloomerJR. Porphyria and porphyrin metabolism. Annu Rev Med1990;41:457. CrossRef

93. BonkowskyH. Porphyrin and heme metabolism and the porphyrias. In: ZakimD, BoyerT(eds). Hepatology: A Textbook of Liver Disease. Philadelphia: WB Saunders; 1982: 351.

94. MooreMR, McCollKE, FitzsimonsEJ, et al.The porphyrias. Blood Rev1990;4:88. CrossRef

95. LimHW, MurphyGM. The porphyrias. Clin Dermatol1996;14:375. CrossRef

96. ElderGH, HiftRJ, MeissnerPN. The acute porphyrias. Lancet1997;349:1613. CrossRef

97. Poh‐FitzpatrickMB. Clinical features of the porphyrias. Clin Dermatol1998;16:251. CrossRef

98. BeckerDM, KramerS. The neurological manifestations of porphyria: a review. Medicine (Baltimore)1977;56:411. CrossRef

99. CavanaghJ, MellickR. On the nature of peripheral nerve lesions associated with acute intermittent porphyria. J Neurol Neurosurg Psychiatry1965;28:320. CrossRef

100. MustajokiP, SeppalainenAM. Neuropathy in latent hereditary hepatic porphyria. Br Med J1975;2:310. CrossRef

101. MeyerUA, SchuurmansMM, LindbergRL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis1998;18:43. CrossRef

102. BonkowskyHL, SchadyW. Neurologic manifestations of acute porphyria. Semin Liver Dis1982;2:108. CrossRef

103. BiempicaL, KosowerN, MaMH, et al.Hepatic porphyrias. Cytochemical and ultrastructural studies of liver in acute intermittent porphyria and porphyria cutanea tarda. Arch Pathol1974;98:336.

104. OstrowskiJ, KostrzewskaE, MichalakT, et al.Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology1983;85:1131.

105. SongCS, MosesHL, RosenthalAS, et al.The influence of postnatal development on drug‐induced hepatic porphyria and the synthesis of cytochrome P‐450. A biochemical and morphological study. J Exp Med1971;134:1349. CrossRef

106. IshakK, SharpH. Metabolic errors and liver disease. In: MacSweenR, AnthonyP, ScheuerP(eds). Pathology of the liver. Edinburgh: Churchill Livingstone; 1987: 101.

107. CampbellJ. The pathology of South African generic porphyria. S Afr J Lab Clin Med1963;9:97.

108. LithnerF, WetterbergL. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand1984;215:271. CrossRef

109. MustajokiP, DesnickRJ. Genetic heterogeneity in acute intermittent porphyria: characterisation and frequency of porphobilinogen deaminase mutations in Finland. Br Med J (Clin Res Ed)1985;291:505. CrossRef

110. KauppinenR, MustajokiP. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore)1992;71:1.

111. BalwaniM, DesnickRJ. The porphyrias: advances in diagnosis and treatment. Blood2012;120:4496. CrossRef

112. DharGJ, BossenmaierI, PetrykaZJ, et al.Effects of hematin in hepatic porphyria. Further studies. Ann Intern Med1975;83:20. CrossRef

113. ThunellS, HenrichsonA, FloderusY, et al.Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem1992;30:599.

114. SassaS. ALAD porphyria. Semin Liver Dis1998;18:95. CrossRef

115. YoungJW, ConteET. Porphyrias and porphyrins. Int J Dermatol1991;30:399. CrossRef

116. BodanessRS, ChanPC. Singlet oxygen as a mediator in the hematoporphyrin‐catalyzed photooxidation of NADPH to NADP+ in deuterium oxide. J Biol Chem1977;252:8554.

117. SandbergS, RomsloI. Porphyrin‐induced photodamage at the cellular and the subcellular level as related to the solubility of the porphyrin. Clin Chim Acta1981;109:193. CrossRef

118. AllisonAC, MagnusIA, YoungMR. Role of lysosomes and of cell membranes in photosensitization. Nature1966;209:874. CrossRef

119. CoppolaA, ViggianiE, SalzaruloL, et al.Ultrastructural changes in lymphoma cells treated with hematoporphyrin and light. Am J Pathol1980;99:175.

120. LimHW, GigliI, WassermanSI. Differential effects of protoporphyrin and uroporphyrin on murine mast cells. J Invest Dermatol1987;88:281. CrossRef

121. DraganiTA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol2010;52:252. CrossRef

122. KlatskinG, ConnH. Hepatic lesions in disorders of porphyrin metabolism. In: KlatskinG, ConnH(eds). Histopathology of the Liver. New York: Oxford Press; 1993: 251.

123. SalataH, CortésJM, Enríquez de SalamancaR, et al.Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J Hepatol1985;1:477. CrossRef

124. RankJM, StrakaJG, BloomerJR. Liver in disorders of porphyrin metabolism. J Gastroenterol Hepatol1990;5:573. CrossRef

125. SingalAK, Kormos‐HallbergC, LeeC, et al.Low‐dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol2012;10:1402. CrossRef

126. SassaroliM, da CostaR, VäänänenH, et al.Distribution of erythrocyte free porphyrin content in erythropoietic protoporphyria. J Lab Clin Med1992;120:614.

127. PiomelliS, LamolaAA, Poh‐FitzpatrickMF, et al.Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. J Clin Invest1975;56:1519. CrossRef

128. AvnerDL, BerensonMM. Hepatic clearance and biliary secretion of protoporphyrin in the isolated, in situ‐perfused rat liver. J Lab Clin Med1982;99:885.

129. MinderEI, Schneider‐YinX, SteurerJ, et al.A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy‐Le‐Grand)2009;55:84.

130. BloomerJR. The liver in protoporphyria. Hepatology1988;8:402. CrossRef

131. BloomerJR, PhillipsMJ, DavidsonDL, et al.Hepatic disease in erythropoietic protoporphyria. Am J Med1975;58:869. CrossRef

132. CrippsDJ, GilbertLA, GoldfarbSS. Erythropoietic protoporphyria: juvenile protoporphyrin hepatopathy cirrhosis and death. J Pediatr1977;91:744. CrossRef

133. FrankM, DossMO. Severe liver disease in protoporphyria. Curr Probl Dermatol1991;20:160. CrossRef

134. RademakersLH, CletonMI, KooijmanC, et al.Ultrastructural aspects of the liver in erythrohepatic protoporphyria. Curr Probl Dermatol1991;20:154. CrossRef

135. HolmeSA, ThomasC, WhatleyS, et al.Symptomatic response of erythropoietic protoporphyria to iron supplementation. J Am Acad Dermatol2007;56:1070. CrossRef

136. BloomerJR, PierachCA. Effect of hematin administration to patients with protoporphyria and liver disease. Hepatology1982;2:817. CrossRef

137. CoxTM, AlexanderGJ, SarkanyRP. Protoporphyria. Semin Liver Dis1998;18:85. CrossRef

138. BloomerJR, WeimerMK, BossenmaierIC, et al.Liver transplantation in a patient with protoporphyria. Gastroenterology1989;97:188.

139. DowmanJK, GunsonBK, MirzaDF, et al.UK experience of liver transplantation for erythropoietic protoporphyria. J Inherit Metab Dis2011;34:539. CrossRef

140. RandEB, BuninN, CochranW, et al.Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics2006;118:e1896. CrossRef

141. WahlinS, AschanJ, BjörnstedtM, et al.Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol2007;46:174. CrossRef

142. NordmannY, DeybachJC. Congenital erythropoietic porphyria. Semin Dermatol1986;5:106.

143. ParadisK, MitchellG, RussoP. Tyrosinemia. In: SuchyFJ(ed). Liver Disease in Children. St. Louis, MO: CV Mosby; 1994: 803.

144. KvittingenEA. Hereditary tyrosinemia type I – an overview. Scand J Clin Lab Invest Suppl1986;184:27.

145. Dupuis‐GirodS, AkkariV, GedC, et al.Successful match‐unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Gunther disease). Eur J Pediatr2005;164:104. CrossRef

146. KatugampolaRP, BadmintonMN, FinlayAY, et al.Congenital erythropoietic porphyria: a single‐observer clinical study of 29 cases. Br J Dermatol2012;167:901. CrossRef

147. De BraekeleerM, LarochelleJ. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay‐Lac‐St‐Jean. Am J Hum Genet1990;47:302.

148. SassaS, FujitaH, KappasA. Succinylacetone and delta‐aminolevulinic acid dehydratase in hereditary tyrosinemia: immunochemical study of the enzyme. Pediatrics1990;86:84.

149. SassaS, KappasA. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta‐aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest1983;71:625. CrossRef

150. RussoPA, MitchellGA, TanguayRM. Tyrosinemia: a review. Pediatr Dev Pathol2001;4:212. CrossRef

151. MitchellG, LarochelleJ, LambertM, et al.Neurologic crises in hereditary tyrosinemia. N Engl J Med1990;322:432. CrossRef

152. van SpronsenFJ, ThomasseY, SmitGP, et al.Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology1994;20:1187. CrossRef

153. AroraN, StumperO, WrightJ, et al.Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis2006;29:54. CrossRef

154. GrompeM, St.‐LouisM, DemersSI, et al.A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med1994;331:353. CrossRef

155. de LaetC, Dionisi‐ViciC, LeonardJV, et al.Spiekerkötter U. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis2013;8:8. CrossRef

156. MitchellJ, ParizeaultG, PelletierL, et al.Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab2012;107:49. CrossRef

157. GrompeM, LindstedtS, Al‐DhalimyM, et al.Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet1995;10:453. CrossRef

158. Masurel‐PauletA, Poggi‐BachJ, RollandMO, et al.NTBC treatment in tyrosinaemia type I: long‐term outcome in French patients. J Inherit Metab Dis2008;31:81. CrossRef

159. LeslieND. Insights into the pathogenesis of galactosemia. Annu Rev Nutr2003;23:59. CrossRef

160. BoschAM. Classical galactosaemia revisited. J Inherit Metab Dis2006;29:516. CrossRef

161. Fridovich‐KeilJL, GubbelsCS, SpencerJB, et al.Ovarian function in girls and women with GALT‐deficiency galactosemia. J Inherit Metab Dis2011;34:357. CrossRef

162. FriedmanJH, LevyHL, BoustanyRM. Late onset of distinct neurologic syndromes in galactosemic siblings. Neurology1989;39:741. CrossRef

163. BerryGT, NissimI, LinZ, et al.Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet1995;346:1073. CrossRef

164. ForgesT, Monnier‐BarbarinoP, LeheupB, et al.Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update2006;12:573. CrossRef

165. FroeschER. Hereditary fructose intolerance: an inborn defect of hepatic fructose‐1‐phosphate splitting aldolase. Am J Med1963;34:151. CrossRef

166. CrossNC, de FranchisR, SebastioG, et al.Molecular analysis of aldolase B genes in hereditary fructose intolerance. Lancet1990;335:306. CrossRef

167. Van den BergheG. Inborn errors of fructose metabolism. Annu Rev Nutr1994;14:41. CrossRef

168. TolanDR. Molecular basis of hereditary fructose intolerance: mutations and polymorphisms in the human aldolase B gene. Hum Mutat1995;6:210. CrossRef

169. BaerlocherK, GitzelmannR, SteinmannB, et al.Hereditary fructose intolerance in early childhood: a major diagnostic challenge. Survey of 20 symptomatic cases. Helv Paediatr Acta1978;33:465.

170. OdievreM, GentilC, GautierM, et al.Hereditary fructose intolerance in childhood. Diagnosis, management, and course in 55 patients. Am J Dis Child1978;132:605. CrossRef

171. Kullberg‐LindhC, HannounC, LindhM. Simple method for detection of mutations causing hereditary fructose intolerance. J Inherit Metab Dis2002;25:571. CrossRef

172. MockDM, PermanJA, ThalerM, et al.Chronic fructose intoxication after infancy in children with hereditary fructose intolerance. A cause of growth retardation. N Engl J Med1983;309:764. CrossRef

173. PhillipsMJ, LittleJA, PtakTW. Subcellular pathology of hereditary fructose intolerance. Am J Med1968;44:910. CrossRef

174. Ogier de BaulnyH. Management and emergency treatments of neonates with a suspicion of inborn errors of metabolism. Semin Neonatol2002;7:17. CrossRef

175. ChenYT, BurchellA. Glycogen storage diseases. In: ScriverC, et al. (eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw‐Hill; 1995: 935.

176. RestainoI, KaplanBS, StanleyC, et al.Nephrolithiasis, hypocitraturia, and a distal renal tubular acidification defect in type 1 glycogen storage disease. J Pediatr1993;122:392. CrossRef

177. ChenYT, ScheinmanJI, ParkHK, et al.Amelioration of proximal renal tubular dysfunction in type I glycogen storage disease with dietary therapy. N Engl J Med1990;323:590. CrossRef

178. KoeberlDD, KishnaniPS, ChenYT. Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis2007;30:159. CrossRef

179. ChenYT, CornblathM, SidburyJB. Cornstarch therapy in type I glycogen‐storage disease. N Engl J Med1984;310:171. CrossRef

180. FernandesJ, LeonardJV, MosesSW, et al.Glycogen storage disease: recommendations for treatment. Eur J Pediatr1988;147:226. CrossRef

181. HaydeM, WidhalmK. Effects of cornstarch treatment in very young children with type I glycogen storage disease. Eur J Pediatr1990;149:630. CrossRef

182. SchwenkWF, HaymondMW. Optimal rate of enteral glucose administration in children with glycogen storage disease type I. N Engl J Med1986;314:682. CrossRef

183. SmitGP, BergerR, PotasnickR, et al.The dietary treatment of children with type I glycogen storage disease with slow release carbohydrate. Pediatr Res1984;18:879. CrossRef

184. WolfsdorfJI, KellerRJ, LandyH, et al.Glucose therapy for glycogenosis type 1 in infants: comparison of intermittent uncooked cornstarch and continuous overnight glucose feedings. J Pediatr1990;117:384. CrossRef

185. WolfsdorfJI, EhrlichS, LandyHS, et al.Optimal daytime feeding regimen to prevent postprandial hypoglycemia in type 1 glycogen storage disease. Am J Clin Nutr1992;56:587.

186. RoshJR, CollinsJ, GroismanGM, et al.Management of hepatic adenoma in glycogen storage disease Ia. J Pediatr Gastroenterol Nutr1995;20:225. CrossRef

187. KoeberlDD. In search of proof‐of‐concept: gene therapy for glycogen storage disease type Ia. J Inherit Metab Dis2012;35:671. CrossRef

188. AmbrusoDR, McCabeER, AndersonD, et al.Infectious and bleeding complications in patients with glycogenosis Ib. Am J Dis Child1985;139:691.

189. BeaudetAL, AndersonDC, MichelsVV, et al.Neutropenia and impaired neutrophil migration in type IB glycogen storage disease. J Pediatr1980;97:906. CrossRef

190. KilpatrickL, GartyBZ, LundquistKF, et al.Impaired metabolic function and signaling defects in phagocytic cells in glycogen storage disease type 1b. J Clin Invest1990;86:196. CrossRef

191. PotashnikR, MoranA, MosesSW, et al.Hexose uptake and transport in polymorphonuclear leukocytes from patients with glycogen storage disease Ib. Pediatr Res1990;28:19. CrossRef

192. RoeTF, CoatesTD, ThomasDW, et al.Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony‐stimulating factors. N Engl J Med1992;326:1666. CrossRef

193. HaagsmaEB, SmitGP, Niezen‐KoningKE, et al.Type IIIb glycogen storage disease associated with end‐stage cirrhosis and hepatocellular carcinoma. The Liver Transplant Group. Hepatology1997;25:537. CrossRef

194. DemoE, FrushD, GottfriedM, et al.Glycogen storage disease type III‐hepatocellular carcinoma a long‐term complication?J Hepatol2007;46:492. CrossRef

195. VertilusSM, AustinSL, FosterKS, et al.Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time. Genet Med2010;12:413. CrossRef

196. GoldsteinJL, AustinSL, BoyetteK, et al.Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with Glycogen Storage Disease Type III. Genet Med2010;12:424. CrossRef

197. ShenJJ, ChenYT. Molecular characterization of glycogen storage disease type III. Curr Mol Med2002;2:167. CrossRef

198. McAdamsAJ, WilsonHE. The liver in generalized glycogen storage disease. Light microscopic observations. Am J Pathol1966;49:99.

199. KishnaniPS, AustinSL, ArnP, et al.ACMG. Glycogen storage disease type III diagnosis and management guidelines. Genet Med2010;12:446. CrossRef

200. BrownBI, BrownDH. Lack of an alpha‐1,4‐glucan: alpha‐1,4‐glucan 6‐glycosyl transferase in a case of type IV glycogenosis. Proc Natl Acad Sci U S A1966;56:725. CrossRef

201. MosesSW, ParvariR. The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr Mol Med2002;2:177. CrossRef

202. BaoY, KishnaniP, WuJY, et al.Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen‐branching enzyme gene. J Clin Invest1996;97:941. CrossRef

203. GreeneHL, BrownBI, McClenathanDT, et al.A new variant of type IV glycogenosis: deficiency of branching enzyme activity without apparent progressive liver disease. Hepatology1988;8:302. CrossRef

204. ReedGBJr, DixonJF, NeusteinJB, et al.Type IV glycogenosis. Patient with absence of a branching enzyme alpha‐1,4‐glucan:alpha‐1,4‐glucan 6‐glycosyl transferase. Lab Invest1968;19:546.

205. SelbyR, StarzlTE, YunisE, et al.Liver transplantation for type IV glycogen storage disease. N Engl J Med1991;324:39. CrossRef

206. StarzlTE, DemetrisAJ, TruccoM, et al.Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med1993;328:745. CrossRef

207. MaternD, StarzlTE, ArnaoutW, et al.Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr1999;158(Suppl 2):S43. CrossRef

208. WillotS, MarchandV, RasquinA, et al.Systemic progression of type IV glycogen storage disease after liver transplantation. J Pediatr Gastroenterol Nutr2010;51:661. CrossRef

209. SokalEM, Van HoofF, AlbertiD, et al.Progressive cardiac failure following orthotopic liver transplantation for type IV glycogenosis. Eur J Pediatr1992;151:200. CrossRef

210. KagalwallaAF, KagalwallaYA, al AjajiS, et al.Phosphorylase b kinase deficiency glycogenosis with cirrhosis of the liver. J Pediatr1995;127:602. CrossRef

211. BurwinkelB, BakkerHD, HerschkovitzE, et al.Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am J Hum Genet1998;62:785. CrossRef

212. LeeWS, SokolRJ. Mitochondrial hepatopathies: advances in genetics, therapeutic approaches, and outcomes. J Pediatr2013;163:942. CrossRef

213. LeonardJV, SchapiraAH. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet2000;355:389. CrossRef

214. Cormier‐DaireV, ChretienD, RustinP, et al.Neonatal and delayed‐onset liver involvement in disorders of oxidative phosphorylation. J Pediatr1997;130:817. CrossRef

215. Garcia‐CazorlaA, De LonlayP, NassogneMC, et al.Long‐term follow‐up of neonatal mitochondrial cytopathies: a study of 57 patients. Pediatrics2005;116:1170. CrossRef

216. ValnotI, OsmondS, Gigarel, N, et al.Mutations of the SCO1 gene in mitochondrial cytochrome oxidase deficiency with neonatal‐onset hepatic failure and encephalopathy. Am J Hum Genet2000;67:1104.

217. de LonlayP, ValnotI, BarrientosA, et al.A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. Nat Genet2001;29:57. CrossRef

218. LeeWS, SokolRJ. Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology2007;45:1555. CrossRef

219. MorrisAA, TaanmanJW, BlakeJ, et al.Liver failure associated with mitochondrial DNA depletion. J Hepatol1998;28:556. CrossRef

220. LabartheF, DobbelaereD, DevismeL, et al.Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. J Hepatol2005;43:333. CrossRef

221. NarkewiczMR, SokolRJ, BeckwithB, et al.Liver involvement in Alpers disease. J Pediatr1991;119:260. CrossRef

222. GaroneC, RubioJC, CalvoSE, et al.MPV17 mutations causing adult‐onset multisystemic disorder with multiple mitochondrial DNA deletions. Arch Neurol2012;69:1648. CrossRef

223. HardingBN. Progressive neuronal degeneration of childhood with liver disease (Alpers‐Huttenlocher syndrome): a personal review. J Child Neurol1990;5:273. CrossRef

224. NaviauxRK, NguyenKV. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Ann Neurol2004;55:706. CrossRef

225. HolveS, HuD, ShubM, et al.Liver disease in Navajo neuropathy. J Pediatr1999;135:482. CrossRef

226. SingletonR, HelgersonSD, SnyderRD, et al.Neuropathy in Navajo children: clinical and epidemiologic features. Neurology1990;40:363. CrossRef

227. KaradimasCL, VuTH, HolveSA, et al.Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am J Hum Genet2006;79:544. CrossRef

228. MollestonJP, SokolRJ, KarnsakulW, et al. for the Childhood Liver Disease Research and Education Network (ChiLDREN)Evaluation of the child with suspected mitochondrial liver disease. J Pediatr Gastroenterol Nutr2013;57:269. CrossRef

229. PfefferG, MajamaaK, TurnbullDM, et al.Treatment for mitochondrial disorders. Cochrane Database Syst Rev2012;18:CD004426.

230. SokalEM, SokolR, CormierV, et al.Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr1999;158(Suppl 2):S81. CrossRef

231. FreeseDK. Porphyrins and porphyria. In: SuchyFJ, SokolRJ, BalistreriWF(eds)Liver Disease in Children. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001, 649.